Boston Scientific Corporation announces the appointment of Warren Wang as senior vice president and president, Asia Pacific, effective January 1, 2018. He will serve as a member of the Boston Scientific executive committee and have responsibility for overseeing the company’s continued growth in the Asia Pacific region.
With extensive experience in the medical technology industry, Warren currently serves as president and managing director, North Asia, Boston Scientific, and leads the company’s business in China, Hong Kong, Taiwan and South Korea. Wang joined Boston Scientific in 2012 as vice president and managing director for China.
“The opportunities and complexities of the Asia Pacific healthcare market offer new inroads and alternatives in the advancement of market appropriate medical technology and access to high quality care,” said Mike Mahoney, chairman and chief executive officer, Boston Scientific. “Warren’s experience and keen sense for developing new business collaborations have had a strong influence on our growth in North Asia. We look forward to Warren’s continued leadership in his new role as we pursue our mission of transforming the lives of patients through our innovative medical solutions.”
Warren will succeed Supratim Bose, who will retire as executive vice president and president, Asia Pacific, Middle East and Africa (AMEA), at the end of 2017.
“I thank Supratim for his many contributions during his distinguished career at Boston Scientific,” said Mahoney. “The AMEA region has grown significantly over the last five years. Supratim’s leadership and commitment to our customers and patients will have lasting impact on Boston Scientific and the medical device industry.”
Prior to joining Boston Scientific, Warren held roles of increasing responsibility with the medical device businesses of Johnson & Johnson, including general manager of the Orthopedics group in China, and leadership positions for the company’s surgical and orthopedics franchises.
Source: Boston Scientific
With a first to market advantage, Ferring’s Rebyota has seen early positive adoption from gastroenterologists and infectious disease specialist in the first month post-launch. As part of their Launch Dynamix™: C.diff service, Spherix reports, while new monthly initiations are modest, a majority of physicians trialing Rebyota report high satisfaction.
Global biopharmaceutical firm UCB has entered an early drug discovery collaboration with Aitia. The collaboration is aimed at discovering and validating new drug targets and drug candidates that are linked to clinical endpoints causally in Huntington’s disease, a debilitating genetic disorder.
Foundry Innovation & Research 1—known by its much catchier acronym, FIRE1—announced Wednesday the close of a $25 million financing round. It was led by a pair of new investors in the company: Andera Partners and Novo Holdings, the holding and investment company that serves as the controlling shareholder for Novo Nordisk and Novozymes.